The evolving role of docetaxel in the management of androgen independent prostate cancer

Journal of Urology

Volumn 170, Issue 5, 2003, Pages 1709-1716

  Khan, Masood A ^a   Carducci, Michael A ^a   Partin, Alan W ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Androgens; Chemotherapy; Prostate; Prostatic neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMITOTIC AGENT; BICALUTAMIDE; CALCITRIOL; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; GONADORELIN DERIVATIVE; HYDROCORTISONE; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SULINDAC SULFONE; TAXOID; THALIDOMIDE; TRASTUZUMAB; WARFARIN;

ABSCESS; ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLITIS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ACTIVITY; DRUG EFFECT; DRUG EXTRAVASATION; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; EPIPHORA; FEBRILE NEUTROPENIA; HUMAN; HYPERGLYCEMIA; HYPERKERATOSIS; INTERSTITIAL PNEUMONIA; LEUKOPENIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; ONYCHOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RASH; REVIEW; SKIN TOXICITY; THROMBOEMBOLISM;

EID: 0141885308     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000088787.95124.4b     Document Type: Review

References (74)

1. Stephenson, R. A.: Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am, 29: 173, 2002
2. Han, M., Partin, A. W., Pound, C. R., Epstein, J. I. and Walsh, P. C.: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am, 25: 555, 2001
3. Coen, J. J., Zietman, A. L., Thakral, H. and Shipley, W. U.: Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol, 20: 3199, 2002
4. Carroll, P. R., Kantoff, P. W., Balk, S. P., Brown, M. A., D'amico, A. V., George, D. J. et al: Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology, suppl., 60: 1, 2002
5. Chodak, G. W., Keane, T. and Klotz, L.: Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology, 60: 201, 2002
6. Kelly, Wm. and Scher, H. I.: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol, 149: 607, 1993
7. Small, E. J., Halabi, S., Picus, J., Dawson, N., Chen, Y., Vogelzang, N. J. et al: A prospective randomized trial of anti-androgen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583. Proc Am Soc Clin Oncol, 20: 174a, 2001
8. Harris, K. A., Weinberg, V., Bok, R. A., Kakefuda, M. and Small, E. J.: Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol, 168: 542, 2002
9. Small, E. J. and Vogelzang, N. J.: Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol, 15: 382, 1997
10. DiPaola, R. S., Patel, J. and Rafi, M. M.: Targeting apoptosis in prostate cancer. Hematol Oncol Clin North Am, 15: 509, 2001
11. Raghaven, D. and Rogers, J.: Update in the management of prostate cancer. Med J Aust, 152: 419, 1990
12. Nehme, A., Varadarajan, P., Sellakumar, G., Gerhold, M., Niedner, H., Zhang, Q. et al: Modulation of docetaxel-induced apoptosis and cell cycle arrest by all-trans retinoic acid in prostate cancer cells. Br J Cancer, 84: 1571, 2001
13. Ferlini, C., Scambia, G., Distefano, M., Filippini, P., Isola, G., Riva, A. et al: Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor cell lines is mediated by the induction of apoptosis. Br J Cancer, 75: 884, 1997
14. Oh, W. K. and Kantoff, P. W.: Management of hormone refractory prostate cancer: current standards and future prospects. J Urol, 160: 1220, 1998
15. Ringel, I. and Horwitz, S. B.: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst, 83: 288, 1991
16. Haldar, S., Basu, A. and Croce, C. M.: bcl is the guardian of microtubule integrity. Cancer Res, 57: 229, 1997
17. Stein, C. A.: Mechanisms of action of taxanes in prostate cancer. Semin Oncol, suppl., 26: 3, 1999
18. Jordan, M. A., Toso, R. J., Thrower, D. and Wilson, L.: Mechanisms of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA, 90: 9552, 1993
19. Jordan, M. A., Wendell, K., Gardiner, S., Derry, W. B., Copp, H. and Wilson, L.: Mitotic block induced by HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res, 56: 816, 1996
20. Riou, J. F., Petitgenet, O., Combeau, C., Lavelle, F. and Rho̊ne-Poulenc Roren, S. A.: Cellular uptake and efflux of docetaxel (Taxotere®) and paclitaxel (Taxol®) in P388 cell line. Proc Am Assoc Cancer Res, 35: 385, 1994
21. Diaz, J. F. and Andreu, J. M.: Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry, 32: 2747, 1993
22. Horowitz, S. B.: Taxol (paclitaxel): mechanisms of action. Ann Oncol, suppl., 5: S3, 1994
23. Manfredi, J. J. and Horowitz, S. B.: Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther, 25: 83, 1984
24. Tsujimoto, Y. and Croce, C. M.: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA, 83: 5214, 1986
25. Pienta, K. J.: Preclinical mechanisms and action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol, suppl., 28: 3, 2001
26. Halder, S., Jena, N. and Croce, C. M.: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA, 92: 4507, 1995
27. Halder, S., Chintapalli, J. and Croce, C. M.: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res, 56: 1253, 1996
28. Krajewski, S., Krajewska, M., Shabaik, A., Wang, H.-G., Irie, S., Fong, L. et al: Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res, 54: 5501, 1994
29. Kraus, L. A., Schmid, S. M., Coffield, R. T., Kern, F., Samuel, S., Dykes, D. J. et al: The mechanism of action of docetaxel and paclitaxel in xenograft models is not limited to Bcl-2 phosphorylation. Proc Am Assoc Cancer Res, 40: 578, 1999
30. Gumerlock, P. H., Mack, P. C., Gustafsson, M. H., Togonon, M. G. and Gandara, D. R.: p27 induction as a potential p53-independent mechanism of apoptotic response to docetaxel in non-small cell lung (NSCLC) and prostate carcinomas (CaP). Clin Cancer Res, suppl., 5: 3859s, 1999
31. Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J. et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol, 14: 1756, 1996
32. Kantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V. et al: Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol, 17: 2506, 1999
33. Picus, J. and Schultz, M.: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol, suppl., 26: 14, 1999
34. Bubley, G. J., Carducci, M. A., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M. et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol, 17: 3461, 1999
35. Friedland, D., Cohen, J., Miller, R., Jr., Voloshin, M., Gluckman, R., Lembersky, B. et al: A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol, suppl., 26: 19, 1999
36. Berry, W., Dakhil, S., Gregurich, M. A. and Asmar, L.: Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol, suppl., 28: 8, 2001
37. Beer, T. M., Pierce, W. C., Lowe, B. A. and Henner, W. D.: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol, 12: 1273, 2001
38. Scholz, M. C., Guess, B., Barrios, F., Strum, S. and Leibowitz, R.: Low-dose, single-agent weekly docetaxel (taxotere) is effective and well tolerated in elderly men with prostate cancer. Proc Am Soc Clin Oncol, 20: 173b, 2001
39. Logothetis, C. J.: Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology, suppl., 16: 63, 2002
40. Dreicer, R. and Klein, E. A.: Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer. Semin Oncol, suppl., 28: 45, 2001
41. Oh, W. K., George, D. J., Kaufman, D. S., Moss, K., Smith, M. R., Richie, J. P. et al: Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol, suppl., 28: 40, 2001
42. Hussain, A., Dawson, N., Amin, P., Naslund, M., Engstrom, C. and Chen, T.: Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results. Semin Oncol, suppl., 28: 22, 2001
43. Read, W. L., Mortimer, J. E. and Picus, J.: Severe interstitial pneumonitis associated with docetaxel administration. Cancer, 94: 847, 2002
44. de Matteis, A., Nuzzo, F., Rossi, E., Landi, G. and Perrone, F.: Intestinal side-effects of docetaxel/vinorelbine combination. Lancet, 355: 1098, 2000
45. Ascherman, J. A., Knowles, S. L. and Attkiss, K.: Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations. Ann Plast Surg, 45: 438, 2000
46. Esmaeli, B., Hortobagyi, G. N., Esteva, F. J., Booser, D., Ahmadi, M. A., Rivera, E. et al: Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology, 109: 1188, 2002
47. Pavithran, K. and Doval, D. C.: Nail changes due to docetaxel. Br J Dermatol, 146: 709, 2002
48. Petrylak, D. P., Macarthur, R. B., O'Connor, J., Shelton, G., Judge, T., Balog, J. et al: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol, 17: 958, 1999
49. Petrylak, D. P., Shelton, G. B., England-Owen, C., Pfaff, C., Bagliella, E., Diuleo, R. et al: Response and preliminary survival results of a phase II study of docetaxel (D)+ estramustine (E) in patients with androgen-independent prostate cancer (AIPCA). Proc Am Soc Clin Oncol, 19: 334a, 2000
50. Sitka Copur, M., Ledakis, P., Lynch, J., Hauke, R., Tarantolo, S., Bolton, M. et al: Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol, suppl., 28: 16, 2001
51. Savarese, D. M., Halabi, S., Hars, V., Akerley, W. L., Taplin, M. E., Godley, P. A. et al: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol, 19: 2509, 2001
52. Sinibaldi, V. J., Carducci, M. A., Moore-Cooper, S., Laufer, M., Zahurak, M. and Eisenberger, M. A.: Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen-independent prostate carcinoma. Cancer, 94: 1457, 2002
53. Taplin, M. E., Bubley, G. J., Rajeshkumar, B., Shuster, T., Ko, Y. J. and Morganstern, D. E.: Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer. Semin Oncol, suppl., 28: 32, 2001
54. Hussain, M., Petrylak, D., Fisher, E., Tangen, C. and Crawford, D.: Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol, suppl., 26: 55, 1999
55. Weinstein, I. B., Lim, J. T., Piazza, G. A., Soh, J. W., Kim, M. G., Yamamoto, H. et al: Selective induction of apoptosis by exisulind in human prostate cancer by a novel mechanism of action. Proc Am Soc Clin Oncol, 18: 355a, 1999
56. Goluboff, E. T., Shabsigh, A., Saidi, J. A., Weinstein, I. B., Mitra, N., Heitjan, D. et al: Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology, 53: 440, 1999
57. Goluboff, E. T., Prager, D., Rukstalis, D., Giantonio, B., Madorsky, M., Barken, I. et al: Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J Urol, 166: 882, 2001
58. Pruitt-Scott, D. E., Ryan, C. W., Stadler, W. M. and Vogelzang, N. J.: Exisulind (EXI) plus docetaxel (DOC) for hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol, 21: 161b, 2002
59. Bariol, C., Meagher, A. P., Vickers, C. R., Byrnes, D. J., Edwards, P. D., Hing, M. et al: Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol, 17: 135, 2002
60. Figg, W. D., Dahut, W., Duray, P., Hamilton, M., Tompkins, A., Steinberg, S. M. et al: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res, 7: 1888, 2001
61. Dahut, W. L., Arlen, P. M., Gulley, J., Parker, C., Fedenko, K., Noone, M. et al: A randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Proc Am Soc Clin Oncol, 21: 183a, 2002
62. Hedlund, T. E., Moffatt, K. A. and Miller, G. J.: Stable expression of the nuclear vitamin D receptor in the human prostate carcinoma cell line JCA-1: evidence that the antiproliferative effect of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signalling pathway. Endocrinology, 137: 1554, 1996
63. Schwartz, G. G., Oeler, T. A., Uskokovic, M. R. and Bahnson, R. R.: Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res, 14: 1077, 1994
64. 3) and paclitaxel: a new therapeutic combination in prostate tumor model systems. Proc Am Soc Clin Oncol, 17: 215a, 1998
65. Rueger, R. M., Hershberger, P. A., Modzelewski, R. A., Johnson, C. S. and Trump, D. L.: The ability of paclitaxel to significantly decrease vitamin D mediated hypercalcemia. Proc Am Assoc Cancer Res, 40: 162, 1999
66. Hershberger, P. A., Yu, W. D., Modzelewski, R. A., Rueger, R. M., Johnson, C. S. and Trump, D. L.: Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res, 7: 1043, 2001
67. Gross, C., Stamey, T., Hancock, S. and Feldman, D.: Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol, 159: 2035, 1998
68. Beer, T. M., Hough, K. M., Garzotto, M., Lowe, B. A. and Henner, D. W.: Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol, suppl., 28: 49, 2001
69. Beer, T. M., Eilers, K. M., Garzotto, M., Lowe, B. A. and Henner, D. W.: Androgen-independent prostate cancer (AIPC) treatment with weekly high-dose calcitriol and docetaxel. Proc Am Soc Clin Oncol, 21: 707, 2002
70. Small, E. J., Bok, R., Reese, D. M., Sudilovsky, D. and Frohlich, M.: Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin Oncol, suppl., 28: 71, 2001
71. Senzer, N. N.: Prostate cancer: multimodality approaches with docetaxel. Semin Oncol, suppl., 28: 77, 2001
72. O'Donnell, R. T., DeNardo, S. J., Miers, L. A., Lamborn, K. R., Kukis, D. L., DeNardo, G. L. et al: Combined modality radio-immunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate, 50: 27, 2002
73. DeNardo, S. J., Kukis, D. L., Kroger, L. A., O'Donnell, R. T., Lamborn, K. R., Miers, L. A. et al: Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA, 94: 4000, 1997
74. O'Donoghue, J. A.: The impact of tumor cell proliferation in radioimmunotherapy. Cancer, 73: 974, 1994